Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy

B-cell maturation antigen (BCMA) plays a promising role as a therapeutic target. In fact, several BCMA-directed therapy modalities, including bispecific antibodies, chimeric-antigen receptor T-cell (CART), and antibody-drug conjugates, are available or in development for patients with relapsed/refractory multiple myeloma (RRMM). Even with the advances in the treatment regime, it is important for oncology teams to understand the implications of the clinical data. Tune into the 1st episode of the Med Table Talk^® Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy, where our leading experts will discuss:

• The rationale, mechanism of action, and efficacy and safety of currently available BCMA-directed therapies
• Prevention and management strategies for adverse events associated with BCMA agents
• The unmet need for representation in clinical trials